MILESTONE PHARMACEUTICALS IN

MISTNASDAQ

🏆 #2862 by market capEarnings Aug 12US Equity

$1.27▲ $0.01 (+0.79%)

Live

1h—

24h▲ 0.8%

7d▲ 11.4%

14d▲ 23.9%

30d▼ 1.6%

1y▼ 23.5%

🏦Market Cap

$158M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

88.3x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $1.25 – $1.29
52-Week Range: $1.00 – $3.06
Volume: $3.26B
Avg Volume: $3.31B
Shares Outstanding: 124.5M
Next Earnings: Sep 2, 2026

Fundamentals Snapshot

Annual Revenue: $2M
Last Q Revenue: $238,000
P/E Ratio: —
P/S Ratio: 88.3x
EPS (TTM): $-0.68
Dividend Yield: —

Why Investors Own MIST

✓High-growth profile — revenue up +6.7% YoY with expanding US Equity exposure.
✓Healthy economics — 49% gross margin and 10% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$2M▲ +2.3% YoY

Gross Margin (TTM)

48.5%▲ +0.9% YoY

Operating Income (TTM)

$279,826▲ +2.3% YoY

Free Cash Flow (TTM)

$153,054▲ +2.3% YoY

About MILESTONE PHARMACEUTICALS IN

Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.

🦦